When does the Praxbind patent expire?
“Praxbind” is brand name for idarucizumab, a monoclonal antibody used to reverse the anticoagulant dabigatran. The exact date of patent expiry depends on country and on which specific patent(s) and exclusivity periods apply (for example, primary patents vs. later improvements). The information provided here does not include Praxbind’s patent numbers, jurisdictions, or expiry dates, so a precise expiry date can’t be confirmed from the available sources.
How can I check Praxbind’s patent expiry date for my country?
To find the correct expiry, you need:
- The country/region (e.g., US, EU, UK, Japan).
- The patent family covering idarucizumab (not just one patent).
- The market authorization/exclusivity regime, which can add additional protection beyond the earliest patent expiry (depending on jurisdiction).
A practical way is to look up:
- Patent registers for idarucizumab and “Praxbind”
- Drug regulator records tied to the product’s authorization and data exclusivity
Does exclusivity end the same day as the patent?
Usually not. Even after a patent expires, some jurisdictions still provide additional time through:
- Supplementary protection certificates (SPCs) or equivalent mechanisms (common in parts of Europe)
- Data exclusivity or market exclusivity rules
Because the exact jurisdiction and product-specific filings aren’t given here, the relationship between Praxbind’s patent expiry and any exclusivity cannot be stated with confidence.
What happens to generic or biosimilar competition after expiry?
Idarucizumab is a biologic, so “generic” typically isn’t the right term. After the relevant protections lapse, companies may pursue:
- Biosimilar approvals (where permitted by law and requirements)
- Full marketing only after patent/exclusivity barriers are cleared, unless there’s a legal workaround (which depends on local regimes)
The timing and whether new entrants can launch immediately depend on the full set of patents and any exclusivity.
Can patents expire earlier than expected (or be extended)?
Yes, patent timelines can shift due to:
- Patent term adjustments and filings that affect term
- Patent disputes/litigation
- Coverage of additional claims in different jurisdictions
- Regulatory extensions tied to product lifecycle protections (varies by country)
What I need to give you the exact expiry date
If you share:
1) the country (or countries) you care about, and
2) whether you mean first patent expiry or last expiry across the patent family,
I can narrow to the correct expiry window.